Transgene SA of France has appointed Alessandro Riva, the current chairman, as chairman and chief executive officer, and confirmed its commitment to its oncolytic virus portfolio. This follows a decision by AstraZeneca Plc to end a research and development collaboration with the company and hand back an oncolytic virus asset poised to start clinical development in the US. According to Transgene, AstraZeneca took the decision after a strategic review of its pipeline. The French company said the decision would have a “limited impact” on its financial guidance.
